For example, Xiang et al. reported that brusatol abrogate gemcitabine-induced NRF2 activation in pancreatic cancer cells and potentiates gemcitabine-induced cell growth inhibition in vitro and xenograft tumor growth inhibition in vivo with reduced NRF2 expression in brusatol-treated xenograft tumors [108]; Yang, et al. reported that brusatol synergistically enhanced the antitumor activity of trastuzumab against HER2-positive cancer cells [109]; trastuzumab markedly enhanced brusatol-induced ROS accumulation and apoptosis level [109]. Here, NFE2L2 is linked to neoplasm.